CISCRP Announces Updated Version of Patient and Family Clinical Trials Guide
The Gift of Participation, a guide for patients and family about the clinical trials has been updated to include new information.
The Center for Information & Study on Clinical Research Participation (CISCRP) has announced the updated version of The Gift of Participation is now available. 'The Gift' was written as a guide for patients and their families considering participation in clinical trials. It was also written as a resource for professionals to use when discussing the clinical research process with their patients and the public. This new edition contains updated chapters and includes new material about social media use in clinical trials; the Sunshine Act and new laws about clinical trials data disclosure and transparency.
During the past five years, more than 200,000 copies of the first edition have been purchased and distributed. All of the proceeds from the book's sales are donated to CISCRP to support its public education and outreach initiatives.
Click here for more information or to order the book.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
